Get the Stockscreener App
0.8388
3.89%
-0.034
Akebia Therapeutics Inc stock is traded at $0.8388, with a volume of 3.38M.
It is down -3.89% in the last 24 hours and down -37.40% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$0.8728
Open:
$0.87
24h Volume:
3.38M
Relative Volume:
0.66
Market Cap:
$232.42M
Revenue:
$232.40M
Net Income/Loss:
$-20.51M
P/E Ratio:
-10.88
EPS:
-0.0771
Net Cash Flow:
$60.04M
1W Performance:
-0.61%
1M Performance:
-37.40%
6M Performance:
-30.10%
1Y Performance:
-74.19%
1-Day Range:
$0.814
$0.88
1-Week Range:
$0.814
$0.949
52-Week Range:
$0.814
$3.32
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
0.8388 | 241.86M | 232.40M | -20.51M | 60.04M | -0.0771 |
TAK
Takeda Pharmaceutical Co Adr
|
17.36 | 56.30B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.48 | 42.85B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.5825 | 42.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.72 | 30.49B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
507.49 | 21.43B | 3.17B | 1.29B | 1.01B | 27.09 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media
Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC - MarketBeat
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings - MarketBeat
Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr
Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo
Akebia Therapeutics Inc (AKBA) Stock News Today - tradingkey.com
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - MarketBeat
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Analyzing a 340% Potential Upside Amid Healthcare Innovation - directorstalkinterviews.com
Akebia Therapeutics (AKBA) Stock Price Sinks As Losses Deepen Value Doubts - Sahm
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
AKBA Looks 1.6% Overvalued on GF Value™ - GuruFocus
AKBA Looks 1.2% Overvalued on GF Value™ as Market Prices in Mode - GuruFocus
Akebia Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlight - GuruFocus
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... - Yahoo Finance
Is Akebia Therapeutics Inc (AKBA) Overvalued After Q2 Earnings M - GuruFocus
Akebia Therapeutics Q2 Earnings Call Highlights - MarketBeat
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Akebia Therapeutics (NASDAQ:AKBA) Releases Earnings Results - MarketBeat
Akebia Therapeutics: Q2 Earnings Snapshot - Barchart.com
Akebia Therapeutics Inc. R (AX9.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Akebia Therapeutics 2Q 2026: Revenue $49.1M, EPS $(0.03) — 10-Q Summary - TradingView
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Akebia begins trial for three rare kidney diseases; data expected in 2027 - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Akebia initiates phase 2 trial for rare kidney disease drug - Investing.com
Akebia initiates phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases - The Manila Times
Akebia Therapeutics Announces Initiation of a Phase 2 - GlobeNewswire
Akebia Therapeutics And 2 Promising Penny Stocks To Watch - webull.com
Akebia Therapeutics (AKBA) to Announce Earnings on Thursday - MarketBeat
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights - The Manila Times
Akebia Therapeutics Inc (AKBA) Income Statement - tradingkey.com
Akebia Therapeutics Inc (AKBA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Akebia Therapeutics Inc (AKBA) Balance Sheet - TradingKey
Akebia Therapeutics Inc (AKBA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Akebia Therapeutics Inc (AKBA) Cash Flow - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.220| - TradingKey
Akebia Therapeutics Inc (AKBA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Akebia Therapeutics Inc (AKBA) Institutional Confidence - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.290|Chg%:+0.070 - TradingKey
AKBA|Akebia Therapeutics Inc|Price:1.280| - TradingKey
Akebia Therapeutics Inc (AKBA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Akebia Therapeutics, Inc. Revenue Breakdown – SWB:AX9 - TradingView
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Brokerages - MarketBeat
AKBA Q2'26 Earnings: revenue estimate is 48.85M USD - TradingView
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akebia Therapeutics Inc Stock (AKBA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ostrowski Erik | SVP, CFO, CBO & Treasurer |
Jun 29 '26 |
Sale |
1.11 |
56,019 |
62,181 |
616,616 |
1.71%
1.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):